Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matter
Publisher
USA
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA Drug Safety Communications
- Region
- USA
- Scope
- Regulatory
- Published
- September 22, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Safety Communications
Scope: Regulatory
Related coverage
More related coverage
UKHSA and University of Oxford scientists uncover genetic changes in the bacteria causing severe Kent meningococcal disease outbreak
Scientists used genome sequencing to identify genetic changes that may explain the severity of the K...
Voluntary scheme aggregate net sales and payment information: August 2026
Information on how the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG)...
The health impacts from industrial sources of PFAS: a rapid review
A rapid review of evidence on the potential adverse health outcomes from long-term exposure to per-...
Per- and polyfluoroalkyl substances (PFAS): general information
Information about Per- and polyfluoroalkyl substances also known as PFAS